Special Issue

Antibiotic or Antibiotic Adjuvant Synthesis and Antimicrobial Evaluation, 2nd Edition

Message from the Guest Editor

Antibiotic or Antibiotic Adjuvant Synthesis and Antimicrobial Evaluation, 2nd Edition will explore recent advances in the design, synthesis, and biological evaluation of antimicrobial compounds, focusing on both natural and synthetic molecules, including those inspired by or derived from marine organisms, plants, and other biological sources, as well as entirely man-made chemical entities. One of the central themes of this Special Issue will be the study of structure–activity relationships (SAR), which provide crucial insights into how the molecular features of these compounds influence their antimicrobial effectiveness. The aim of this Special Issue is to gather interdisciplinary contributions from the fields of chemistry, biology, and pharmacology that address the urgent need for novel antimicrobial strategies. We thus welcome contributions that explore novel scaffolds, the modification of known antibiotics, or innovative adjuvants, and invite researchers involved in medicinal chemistry, microbiology, natural product chemistry, and drug discovery to submit their work

Guest Editor

Dr. Jean Michel Brunel

UMR_MD1, Faculté de Pharmacie, Aix-Marseille Universite, 27 Bd Jean Moulin, CEDEX 5, 13385 Marseille, France

Deadline for manuscript submissions

31 January 2026

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/si/247238

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/antibiotics

Antibiotics

an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed

mdpi.com/journal/antibiotics

About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon
School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

MDPI